Warfarin vs. Apixaban		Dabigatran vs. Apixaban		Rivaroxaban vs. Apixaban
Dosing Form	n = 76,940	P Valuea	n = 41,580	P Valuea	n = 77,640	P Valuea
All-cause hospitalization
Standard doseb	1.33 (1.28-1.38)	< 0.001	1.13 (1.07-1.19)	0.409	1.21 (1.17-1.26)	0.230
Low doseb	1.09 (1.03-1.16)		1.18 (1.08-1.28)		1.17 (1.11-1.23)
Stroke/SE
Standard dose	2.55 (1.99-3.26)	0.039	1.50 (1.08-2.10)	0.914	1.48 (1.13-1.94)	0.408
Low dose	1.67 (1.22-2.29)		1.46 (0.95-2.23)		1.25 (0.92-1.69)
Major bleeding
Standard dose	1.93 (1.70-2.19)	0.003	1.44 (1.19-1.74)	0.782	1.90 (1.67-2.17)	0.678
Low dose	1.38 (1.16-1.65)		1.51 (1.16-1.97)		1.82 (1.55-2.13)
Censoring at 6 months	n = 76,940	P Value	n = 41,580	P Value	n = 77,640	P Value
All-cause hospitalization	1.28 (1.24-1.32)	< 0.001	1.14 (1.09-1.20)	< 0.001	1.24 (1.20-1.29)	< 0.001
Stroke/SE	2.22 (1.80-2.74)	< 0.001	1.43 (1.08-1.90)	0.013	1.33 (1.05-1.67)	0.017
Major bleeding	1.74 (1.56-1.95)	< 0.001	1.39 (1.18-1.65)	< 0.001	1.85 (1.65-2.06)	< 0.001
At least 30-day follow up	n = 68,536	P Value	n = 36,882	P Value	n = 68,684	P Value
All-cause hospitalization	1.25 (1.21-1.29)	< 0.001	1.11 (1.06-1.16)	< 0.001	1.19 (1.15-1.23)	< 0.001
Stroke/SE	2.21 (1.81-2.70)	< 0.001	1.43 (1.08-1.88)	0.001	1.43 (1.16-1.77)	< 0.001
Major bleeding	1.72 (1.55-1.91)	< 0.001	1.42 (1.21-1.66)	< 0.001	1.87 (1.69-2.07)	< 0.001

Note: In the sensitivity analysis of dosing forms, standard-dose and low-dose dabigatran and rivaroxaban were compared with apixaban patients with the same dose.

^aP value is for interaction in the dosing form sensitivity analysis.

^bStandard dose: 5 mg twice a day apixaban, 150 mg twice a day dabigatran, 20 mg every day rivaroxaban; low dose: 2.5 mg twice a day apixaban, 75 mg twice a day dabigatran, 10 mg or 15 mg every day rivaroxaban.

SE = systemic embolism.